10-Q: Bio-Techne Q2 Earnings Flat, Profitability Initiatives Drive EPS Growth

Bio-Techne Corporation reports flat net sales for the quarter ended December 31, 2025, with diluted EPS increasing to $0.24, driven by cost management and divestitures.

Summary

• Consolidated net sales for the quarter ended December 31, 2025, remained flat at $295.9 million compared to $297.0 million in the prior year period.
• Consolidated net sales for the six months ended December 31, 2025, decreased 1% to $582.4 million from $586.5 million in the prior year period.
• Organic revenue for the quarter ended December 31, 2025, was flat, with a 2% favorable impact from foreign currency and a 2% unfavorable impact from a business held-for-sale.
• Diluted earnings per share (EPS) increased to $0.24 for the quarter ended December 31, 2025, from $0.22 in the prior year period.
• Diluted EPS for the six months ended December 31, 2025, increased to $0.49 from $0.42 in the prior year period.
• Operating income for the quarter ended December 31, 2025, increased to $54.5 million from $47.4 million in the prior year period.
• Operating income for the six months ended December 31, 2025, increased to $102.1 million from $87.4 million in the prior year period.
• Selling, general and administrative (SG&A) expenses decreased 6% for the quarter and 4% for the six months, primarily due to ongoing cost management initiatives.
• Research and development (R&D) expenses decreased 8% for the quarter and 3% for the six months, while continuing strategic growth investments.
• The Protein Sciences segment's net sales increased 2% for the quarter but remained flat for the six months, with operating margin decreasing due to unfavorable product mix.
• The Diagnostics and Spatial Biology segment's net sales decreased 4% for both the quarter and six months, but organic growth was 3%, and operating margin significantly improved due to the Exosome Diagnostics divestiture and profitability initiatives.
• Cash and cash equivalents increased to $172.9 million as of December 31, 2025, from $162.2 million as of June 30, 2025.
• Long-term debt obligations were reduced by $86.0 million for the six months ended December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid operational performance. Improved profitability and EPS despite flat sales, driven by effective cost management and strategic portfolio adjustments, indicates strong execution in a challenging revenue environment.

Positives

• Diluted EPS increased to $0.24 for the quarter ended December 31, 2025, from $0.22 in the prior year, and to $0.49 for the six months from $0.42.
• Operating income significantly improved, increasing by $7.1 million for the quarter and $14.7 million for the six months year-over-year.
• Selling, general and administrative expenses decreased by 6% for the quarter and 4% for the six months, reflecting successful cost management initiatives.
• Research and development expenses decreased by 8% for the quarter and 3% for the six months, indicating efficiency while maintaining strategic investments.
• The Diagnostics and Spatial Biology segment achieved 3% organic growth and a significant improvement in operating margin (10.4% vs 3.9% for the quarter, 10.8% vs 4.5% for six months), driven by the Exosome Diagnostics divestiture and profitability initiatives.
• Cash and cash equivalents increased by $10.7 million, reaching $172.9 million as of December 31, 2025.
• Long-term debt obligations were reduced from $346.0 million to $260.0 million.
• The company maintains strong liquidity with $740 million available on its revolving line-of-credit.

Negatives

• Consolidated net sales remained flat for the quarter and decreased 1% for the six months year-over-year.
• Organic revenue for the Protein Sciences segment decreased 1% for the quarter and 2% for the six months.
• The Protein Sciences segment's operating margin decreased due to unfavorable product mix (39.3% vs 41.2% for the quarter, 38.9% vs 40.3% for six months).
• Consolidated gross margins slightly decreased for the quarter (64.6% vs 65.3%) and adjusted gross margins decreased for both periods (68.5% vs 70.5% for the quarter, 69.4% vs 70.0% for six months).
• Cash provided by operating activities decreased to $110.0 million for the six months ended December 31, 2025, from $148.2 million in the prior year.
• The effective income tax rate increased to 25.2% for the quarter and 22.9% for the six months, compared to 18.6% and 17.5% respectively in the prior year.

Risks

• Outcomes of legal actions are not within complete control and may not be known for prolonged periods, potentially resulting in significant expenditures, lost revenues, or limitations on business operations.
• The ultimate cost of accrued litigation could be materially different than current estimates and accruals, potentially having a material adverse impact on consolidated earnings, financial position, and/or cash flows.
• Fluctuations in foreign currency exchange rates can affect actual results of operations.
• Integration of newly acquired businesses poses risks.
• The introduction and acceptance of new products are uncertain.
• General national and international economic, political, regulatory, and other conditions can impact the business.
• Increased competition is a factor in the markets served.
• Reliance on internal manufacturing and related operations carries inherent risks.
• Supply chain challenges could affect operations and product availability.
• The recruitment and retention of qualified personnel are critical for continued success.
• The impact of governmental regulation can affect business operations and compliance costs.
• Maintenance of intellectual property rights is essential for protecting proprietary technologies.
• Credit risk and fluctuation in the market value of the investment portfolio could impact financial performance.
• Unforeseen delays and expenses related to facility construction and improvements could affect capital expenditures and operational efficiency.

Future Outlook

Management expects gross margins to continue to be impacted by the varying growth rates of its portfolio mix. The forecasted tax rate before discrete items for the second fiscal quarter of 2026 is 26.2%, and the consolidated income tax rate for the remainder of fiscal 2026 is expected to range from 25% to 29%, excluding discrete items. The Company anticipates meeting its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for at least the next 12 months through available cash, operating cash flow, and its existing revolving line of credit. Capital expenditures for the remainder of fiscal 2026 are projected to be approximately $18 million, aimed at increasing capacity to meet expected sales growth. The acquisition of the remaining 80.1% equity interest in Wilson Wolf, with an estimated payment of approximately $1 billion plus potential contingent consideration, is forecasted to occur between fiscal 2026 and fiscal 2028.

Management Comments

• "We are committed to providing the life sciences community with innovative, high-quality scientific tools that allow our customers to make extraordinary discoveries and treat and diagnose diseases."
• "We intend to build on Bio-Techne's past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to expand our presence in diagnostics and other adjacent markets."
• "The Company's strategic pillars for long-term growth and profitability are to grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture."
• "We continue to make strategic growth investments in research and development as we also employ our cost management initiatives."
• "Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit."

Industry Context

StockSavvy.ai notes that Bio-Techne operates in the highly competitive and regulated life sciences and diagnostics markets. The flat consolidated sales, despite organic growth in Diagnostics and Spatial Biology, suggest a mixed market environment. The focus on cost management and profitability initiatives aligns with broader industry trends where companies are optimizing operations amidst evolving market demands and economic pressures. The divestiture of Exosome Diagnostics and the strategic investment in Spear Bio indicate a continued portfolio optimization strategy, common in the dynamic biotech sector.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or competitors regarding financial performance or operational metrics.

Legal Proceedings

• The Company and its affiliates are involved in various legal actions, including product liability, employment, intellectual property, commercial disputes, shareholder matters, environmental proceedings, tax disputes, and governmental proceedings and investigations.
• A dispute with a former CEO was resolved through binding arbitration for $37.2 million (inclusive of interest and legal fees) during the quarter ended March 31, 2025.
• A dispute regarding 12,120 shares was resolved for $0.5 million during the quarter ended March 31, 2025.
• Litigation charges were immaterial during the quarter and six months ended December 31, 2025 and 2024.
• As of February 4, 2026, the Company is not a party to any legal proceedings that are reasonably expected to have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Benefit from increased EPS and continued cash dividends ($0.08 per share announced).
• Employees: Impacted by restructuring actions (employee severance mentioned) but also benefit from stock-based compensation plans.
• Customers: Potential benefits from strategic growth investments in R&D and increased capacity to meet expected sales growth.
• Creditors: Improved credit profile due to a reduction in long-term debt obligations by $86.0 million.
• Suppliers: No direct impact on suppliers is explicitly mentioned in the filing.

Next Steps

• Continue to incur costs related to fiscal 2025 restructuring actions through fiscal 2027.
• Adopt ASU 2023-09 (Improvements to Income Tax Disclosures) beginning with the annual report for fiscal 2026.
• Adopt ASU 2024-03 (Income Statement Reporting Comprehensive IncomeExpense Disaggregation Disclosures) beginning with the annual report for fiscal 2028.
• Adopt ASU 2025-05 (Financial InstrumentsCredit Losses) beginning with the annual report for fiscal 2027.
• Adopt ASU 2025-06 (IntangiblesGoodwill and OtherInternal-Use Software) beginning with the annual report for fiscal 2029.
• Payment of an $0.08 per share cash dividend on February 27, 2026, to shareholders of record on February 16, 2026.
• Capital expenditures for the remainder of fiscal 2026 are expected to be approximately $18 million, focused on increasing capacity.
• Acquire the remaining 80.1% equity interest in Wilson Wolf on December 31, 2027, or earlier if certain financial milestones are met, with an estimated payment of approximately $1 billion plus potential contingent consideration between fiscal 2026 and fiscal 2028.

Key Dates

Recommendation

StockSavvy.ai recommends a "hold" for Bio-Techne. The company demonstrated strong operational efficiency, translating flat net sales into improved operating income and diluted EPS through effective cost management and strategic divestitures like Exosome Diagnostics. The Diagnostics and Spatial Biology segment shows promising organic growth and margin expansion. However, the Protein Sciences segment experienced declining organic revenue and reduced operating margins due to unfavorable product mix. The substantial future acquisition obligation for Wilson Wolf, estimated at approximately $1 billion, represents a significant future capital outlay that warrants careful monitoring. While the company is financially sound with ample liquidity, sustained top-line growth across all segments is crucial for a more bullish outlook.

Keywords

Biotechnology, Life Sciences, Reagents, Instruments, Diagnostics, Spatial Biology, Protein Sciences, Earnings, Financial Results, Q2 2026, BIO-TECHNE, TECH, Cost Management, Divestiture, Exosome Diagnostics, Wilson Wolf